Life sciences companies face significant risk under the Foreign Corrupt Practices Act (FCPA) when operating across borders. In 2017, as in the past several years, life sciences companies were a focus for FCPA investigations and settlements, and that focus will remain through 2018. 2017 FCPA enforcement touched on many different areas of a life sciences company’s business operations, including clinical trials, joint ventures, agency relationships, distribution platforms, and mergers and acquisitions.
Register now for this one-hour complimentary webinar with AGG Partner Michael E. Burke as he will review 2017 FCPA enforcement involving life sciences companies, preview 2018’s enforcement landscape, and offer practical solutions to minimize FCPA risk.
There will be an opportunity for Q&A following the presentation.
Credits: This webinar is pending CLE credit by the State Bar of Georgia.